SPX 6,124.35 ▲ 0.47%DJI 44,210.18 ▼ 0.12%CCMP 19,875.02 ▲ 0.72%SX5E 5,231.77 ▲ 0.24%UKX 8,402.11 ▼ 0.22%NKY 39,870.50 ▲ 0.78%EURUSD 1.0842 ▼ 0.19%USGG10YR 4.31 ▲ 0.94%CL1 71.82 ▼ 0.88%XAU 2,685.40 ▲ 0.42%XBT 97,250.00 ▲ 1.93%SPX 6,124.35 ▲ 0.47%DJI 44,210.18 ▼ 0.12%CCMP 19,875.02 ▲ 0.72%SX5E 5,231.77 ▲ 0.24%UKX 8,402.11 ▼ 0.22%NKY 39,870.50 ▲ 0.78%EURUSD 1.0842 ▼ 0.19%USGG10YR 4.31 ▲ 0.94%CL1 71.82 ▼ 0.88%XAU 2,685.40 ▲ 0.42%XBT 97,250.00 ▲ 1.93%
 

← Persons Index

Andreas Struengmann & family
Rank #322 · Healthcare

Andreas Struengmann & family

Pharmaceuticals · Germany

Net worth$10.5B
Today−$22M
7 days−$238K
30 days−$454M

Net worth, last 30 days

Low $10.5BHigh $11.0B

Biography

Andreas Struengmann and twin brother Thomas were early backers of BioNTech, which partnered with Pfizer to make a vaccine for Covid-19.

The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion.

The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.

In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.

Did you know

After studying medicine in Freiburg, Germany, Andreas worked as a doctor in South Africa.

Holdings

CompanyTickerSharesValue
BioNTech Sponsored ADRBNTX-US50,640,000$4.1B
Formycon AGFYB-DE2,124,000$30M
Private assets & other$6.3B

Public holdings ≈ $4.2B. Holdings may include options and overlap between rows.